1-12 of 12
Naiyer A. Rizvi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Han Si, Michael Kuziora, Katie J. Quinn, Elena Helman, Jiabu Ye, Feng Liu, Urban Scheuring, Solange Peters, Naiyer A. Rizvi, Philip Z. Brohawn, Koustubh Ranade, Brandon W. Higgs, Kimberly C. Banks, Vikram K. Chand, Rajiv Raja
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (6): 1631–1640.
https://doi.org/10.1158/1078-0432.CCR-20-3771
Published: 15 March 2021
View article titled, A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Open the PDF for A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Ani S. Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio González-García, Nathan Standifer, Jennifer Cann, Nicholas Durham, Shahram Rahimian, Rakesh Kumar, Crystal S. Denlinger
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6196–6203.
https://doi.org/10.1158/1078-0432.CCR-20-0452
Published: 01 December 2020
View article titled, Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Bonnie S. Glisson, Rom S. Leidner, Robert L. Ferris, John Powderly, Naiyer A. Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James P. Ohr, Jennifer Burton, Yanan Zheng, Steven Eck, Matthew Gribbin, Katie Streicher, Danielle M. Townsley, Sandip Pravin Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5358–5367.
https://doi.org/10.1158/1078-0432.CCR-19-3070
Published: 15 October 2020
View article titled, Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

Alexander Drilon, Lu Wang, Maria E. Arcila, Sohail Balasubramanian, Joel R. Greenbowe, Jeffrey S. Ross, Phil Stephens, Doron Lipson, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Naiyer A. Rizvi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (16): 3631–3639.
https://doi.org/10.1158/1078-0432.CCR-14-2683
Published: 13 August 2015
View article titled, Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Open the PDF for Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches in another window
Includes: Supplementary data
Journal Articles

Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.

Edward B. Garon, Ani Balmanoukian, Omid Hamid, Rina Hui, Leena Gandhi, Natasha Leighl, Matthew Gubens, Jonathan W. Goldman, Gregory M. Lubiniecki, Kenneth Emancipator, Marisa Dolled-Filhart, Jared Lunceford, Kevin Gergich, Naiyer A. Rizvi
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2_Supplement): A20.
https://doi.org/10.1158/1078-0432.14AACRIASLC-A20
Published: 16 January 2014
View article titled, Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.
Journal Articles

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

M. Catherine Pietanza, Kyuichi Kadota, Kety Huberman, Camelia S. Sima, John J. Fiore, Dyana K. Sumner, William D. Travis, Adriana Heguy, Michelle S. Ginsberg, Andrei I. Holodny, Timothy A. Chan, Naiyer A. Rizvi, Christopher G. Azzoli, Gregory J. Riely, Mark G. Kris, Lee M. Krug
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1138–1145.
https://doi.org/10.1158/1078-0432.CCR-11-2059
Published: 14 February 2012
View article titled, Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker
Open the PDF for Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker in another window
Includes: Supplementary data
Journal Articles

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene

Naiyer A. Rizvi, Valerie Rusch, William Pao, Jamie E. Chaft, Marc Ladanyi, Vincent A. Miller, Lee M. Krug, Christopher G. Azzoli, Manjit Bains, Robert Downey, Raja Flores, Bernard Park, Bhuvanesh Singh, Maureen Zakowski, Robert T. Heelan, Ronglai Shen, Mark G. Kris
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3500–3506.
https://doi.org/10.1158/1078-0432.CCR-10-2102
Published: 15 May 2011
View article titled, Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the <em>EGFR</em> Gene
Open the PDF for Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the <em>EGFR</em> Gene in another window
Journal Articles

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

Yelena Y. Janjigian, Christopher G. Azzoli, Lee M. Krug, Leanne K. Pereira, Naiyer A. Rizvi, M Catherine Pietanza, Mark G. Kris, Michelle S. Ginsberg, William Pao, Vincent A. Miller, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2521–2527.
https://doi.org/10.1158/1078-0432.CCR-10-2662
Published: 14 April 2011
View article titled, Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Open the PDF for Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib in another window
Journal Articles

A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development

Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William Pao, Pingzhen Guo, Valerie M. Rusch, Marc Ladanyi, Naiyer A. Rizvi, Lawrence H. Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (18): 4647–4653.
https://doi.org/10.1158/1078-0432.CCR-10-0125
Published: 14 September 2010
View article titled, A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
Open the PDF for A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development in another window
Includes: Supplementary data
Journal Articles

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Gregory J. Riely, Mark G. Kris, Binsheng Zhao, Tim Akhurst, Daniel T. Milton, Erin Moore, Leslie Tyson, William Pao, Naiyer A. Rizvi, Lawrence H. Schwartz, Vincent A. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (17): 5150–5155.
https://doi.org/10.1158/1078-0432.CCR-07-0560
Published: 04 September 2007
View article titled, Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
Open the PDF for Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus in another window
Journal Articles

A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer

Naiyer A. Rizvi, Jeffrey S. Humphrey, Elizabeth A. Ness, Michael D. Johnson, Elora Gupta, Kathleen Williams, Diana J. Daly, Daryl Sonnichsen, Delina Conway, John Marshall, Herbert Hurwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (6): 1963–1970.
https://doi.org/10.1158/1078-0432.CCR-1183-02
Published: 24 March 2004
View article titled, A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer
Open the PDF for A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer in another window
Journal Articles

A Phase I Study of LGD1069 in Adults with Advanced Cancer

Naiyer A. Rizvi, John L. Marshall, William Dahut, Elizabeth Ness, Joseph A. Truglia, Gordon Loewen, George M. Gill, Edgar H. Ulm, Rita Geiser, Dinah Jaunakais, Michael J. Hawkins
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1658–1664.
Published: 01 July 1999
View article titled, A Phase I Study of LGD1069 in Adults with Advanced Cancer
Open the PDF for A Phase I Study of LGD1069 in Adults with Advanced Cancer in another window